MusclePharm Corp Form 8-K August 10, 2015

### **UNITED STATES**

### SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

### FORM 8-K

## **CURRENT REPORT**

**Pursuant to Section 13 or 15(d)** 

of the Securities Exchange Act of 1934

Date of Report: August 10, 2015

(Date of earliest event reported)

## **MusclePharm Corporation**

(Exact name of registrant as specified in its charter)

**NEVADA** 

(State or other jurisdiction

000-53166 (Commission

77-0664193 (IRS Employer

of incorporation)

File Number)

**Identification No.)** 

## Edgar Filing: MusclePharm Corp - Form 8-K

## 4721 Ironton Street, Building A

Denver, Colorado 80239

(Address of principal executive offices) (Zip Code)

(303) 396-6100

(Registrant s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).

### ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

## ITEM 7.01 REGULATION FD DISCLOSURE.

On August 10, 2015, MusclePharm Corporation (the Company) issued a press release announcing results for the quarter ended June 30, 2015. A copy of the press release is attached to this report as Exhibit 99.1 and is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed incorporated by reference into any of the Registrant s registration statements or other filings with the Securities and Exchange Commission, except as shall be expressly set forth by specific reference in such filing.

### ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits.

The exhibit listed in the following Exhibit Index is filed as part of this Current Report on Form 8-K.

#### **Exhibit**

## No. Description

99.1 MusclePharm Corporation Press Release issued August 10, 2015

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## MUSCLEPHARM CORPORATION

Dated: August 10, 2015

By: /s/ Brad J. Pyatt Name: Brad J. Pyatt

Title: Chief Executive Officer